Loading…
Missouri Analytical Laboratories Inc, a contract testing laboratory, received a warning letter for significant Current Good Manufacturing Practice (CGMP) violations related to drugs and active pharmaceutical ingredients. During an inspection in May 2021, the FDA found that the firm failed to thoroughly investigate unexplained discrepancies and out-of-specification test results, instead relying on resampling and retesting to invalidate original failures without establishing root causes or providing adequate scientific justification. The firm's inadequate investigation procedures and lack of proper controls rendered their drugs adulterated under federal law.